460 related articles for article (PubMed ID: 20798865)
1. Molecular and therapeutic potential and toxicity of valproic acid.
Chateauvieux S; Morceau F; Dicato M; Diederich M
J Biomed Biotechnol; 2010; 2010():. PubMed ID: 20798865
[TBL] [Abstract][Full Text] [Related]
2. Hidden pharmacological activities of valproic acid: A new insight.
Singh D; Gupta S; Verma I; Morsy MA; Nair AB; Ahmed AF
Biomed Pharmacother; 2021 Oct; 142():112021. PubMed ID: 34463268
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid selectively suppresses the formation of inhibitory synapses in cultured cortical neurons.
Kumamaru E; Egashira Y; Takenaka R; Takamori S
Neurosci Lett; 2014 May; 569():142-7. PubMed ID: 24708928
[TBL] [Abstract][Full Text] [Related]
4. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid.
Qiao L; Schaack J; Shao J
Endocrinology; 2006 Feb; 147(2):865-74. PubMed ID: 16282359
[TBL] [Abstract][Full Text] [Related]
5. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection.
Monti B; Polazzi E; Contestabile A
Curr Mol Pharmacol; 2009 Jan; 2(1):95-109. PubMed ID: 20021450
[TBL] [Abstract][Full Text] [Related]
6. Experimental studies and controlled clinical testing of valproate and vigabatrin.
Gram L
Acta Neurol Scand; 1988 Oct; 78(4):241-70. PubMed ID: 3146860
[TBL] [Abstract][Full Text] [Related]
7. Structure-function studies for the panacea, valproic acid.
Terbach N; Williams RS
Biochem Soc Trans; 2009 Oct; 37(Pt 5):1126-32. PubMed ID: 19754465
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition.
Jeong MR; Hashimoto R; Senatorov VV; Fujimaki K; Ren M; Lee MS; Chuang DM
FEBS Lett; 2003 May; 542(1-3):74-8. PubMed ID: 12729901
[TBL] [Abstract][Full Text] [Related]
9. Valproic Acid: second generation.
Bialer M; Yagen B
Neurotherapeutics; 2007 Jan; 4(1):130-7. PubMed ID: 17199028
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors.
Dedoni S; Marras L; Olianas MC; Ingianni A; Onali P
J Pharmacol Exp Ther; 2019 Sep; 370(3):490-503. PubMed ID: 31308194
[TBL] [Abstract][Full Text] [Related]
11. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity.
Leng Y; Chuang DM
J Neurosci; 2006 Jul; 26(28):7502-12. PubMed ID: 16837598
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid enhances neuronal differentiation of sympathoadrenal progenitor cells.
Vukićević V; Qin N; Balyura M; Eisenhofer G; Wong ML; Licinio J; Bornstein SR; Ehrhart-Bornstein M
Mol Psychiatry; 2015 Aug; 20(8):941-50. PubMed ID: 25707399
[TBL] [Abstract][Full Text] [Related]
13. Valproic acid inhibits neurosphere formation by adult subventricular cells by a lithium-sensitive mechanism.
Zhou Q; Dalgard CL; Wynder C; Doughty ML
Neurosci Lett; 2011 Aug; 500(3):202-6. PubMed ID: 21741439
[TBL] [Abstract][Full Text] [Related]
14. Valproic Acid Limits Pancreatic Recovery after Pancreatitis by Inhibiting Histone Deacetylases and Preventing Acinar Redifferentiation Programs.
Eisses JF; Criscimanna A; Dionise ZR; Orabi AI; Javed TA; Sarwar S; Jin S; Zhou L; Singh S; Poddar M; Davis AW; Tosun AB; Ozolek JA; Lowe ME; Monga SP; Rohde GK; Esni F; Husain SZ
Am J Pathol; 2015 Dec; 185(12):3304-15. PubMed ID: 26476347
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid exposure leads to upregulation and increased promoter histone acetylation of sepiapterin reductase in a serotonergic cell line.
Balasubramanian D; Deng AX; Doudney K; Hampton MB; Kennedy MA
Neuropharmacology; 2015 Dec; 99():79-88. PubMed ID: 26151765
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid phase shifts the rhythmic expression of Period2::Luciferase.
Johansson AS; Brask J; Owe-Larsson B; Hetta J; Lundkvist GB
J Biol Rhythms; 2011 Dec; 26(6):541-51. PubMed ID: 22215612
[TBL] [Abstract][Full Text] [Related]
17. Modulation of human gamma/delta T-cell activation and phenotype by histone deacetylase inhibitors.
Bhat J; Oberg HH; Kabelitz D
Cell Immunol; 2015 Jul; 296(1):50-6. PubMed ID: 25708484
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid in the complex therapy of malignant tumors.
Hrebackova J; Hrabeta J; Eckschlager T
Curr Drug Targets; 2010 Mar; 11(3):361-79. PubMed ID: 20214599
[TBL] [Abstract][Full Text] [Related]
20. Characterization of valproic acid-initiated homologous recombination.
Sha K; Winn LM
Birth Defects Res B Dev Reprod Toxicol; 2010 Apr; 89(2):124-32. PubMed ID: 20437471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
